AbbVie Ready To Leverage Migraine Franchise In Crowded Market
Qulipta Adds Indication Not Covered By Botox, Ubrelvy
Executive Summary
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.
You may also be interested in...
Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase
Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.
AbbVie Qulipta Shows Benefit In Severely Afflicted Chronic Migraine Patients
The drug could see a competitive edge over other anti-CGRP agents with new chronic migraine data plus convenience as an oral drug and potential for combination with Botox.
Amgen Revenue Boosted By COVID-19 Manufacturing, Flat To Down Without It
The company reported $6.8bn in fourth quarter revenue, missing analyst consensus of $6.9bn even with revenue from supplying Lilly’s COVID-19 antibodies. Enbrel and Aimovig fell by double digits.